Recombinant Hepatocyte Growth Factor Accelerates Cutaneous Wound Healing in Diabetic Mouse Model

Strategic Insights -

Researchers in Japan have discovered that recombinant hepatocyte growth factor (HGF) significantly accelerates cutaneous wound healing in a diabetic mouse model. The study found that topical administration of HGF, along with basic fibroblast growth factor (bFGF), promoted wound closure and re-epithelialization. Notably, HGF treatment enhanced expansion of granulation tissue, stimulated neovascularization, and increased microvessel density, whereas bFGF treatment remained effective even in later stages of wound healing.

Key Takeaways:

  • Recombinant HGF significantly accelerates cutaneous wound healing in a diabetic mouse model.
  • Topical administration of HGF, in conjunction with bFGF, promotes wound closure and re-epithelialization.
  • HGF treatment enhances expansion of granulation tissue and stimulates neovascularization, whereas bFGF treatment remains effective in later stages of wound healing.
  • Microvessel density in HGF-treated wounds was higher than in bFGF-treated wounds on day 7 postwounding.
  • Matrix metalloproteinases (MMP-2 and MMP-9) activities involved in cell migration, angiogenesis, and extracellular matrix (ECM) remodeling were enhanced by HGF-treatment on day 7.
  • DNA synthesis of fibroblasts in granulation tissue was stimulated by bFGF, but not by HGF, suggesting a lesser degree of susceptibility to cutaneous scarring.
  • The authors propose that supplement of HGF may be a potential therapeutic approach for the treatment of cutaneous ulcers.
  • S. Yoshida and colleagues published the results of their research in Growth Factors, a peer-reviewed journal.

Statistics:

  • 22(2):111-119: The journal volume and page range where the study was published, indicating a comprehensive review process.
  • 2004: The year of publication, marking the significance of the study in the context of contemporary research.
  • 7: The number of days postwounding when the study observed enhanced neovascularization and MMP-2/MMP-9 activities.
  • 28: The number of days postwounding when the study observed the extent of granulation tissue in bFGF-treated wounds.

Sources:

  • Yoshida, S., et al. (2004) "Recombinant hepatocyte growth factor accelerates cutaneous wound healing in a diabetic mouse model." Growth Factors, 22(2), 111-119.
  • Taylor & Francis Ltd. (Journal publisher).
  • Osaka University, Graduate School of Medicine, Course Advanced Med, Division Molecular Regenerat Med (Corresponding author's affiliation).
  • Diabetes Week editors (Publication date: 2004).